Tanaya Shree, MD, PhD, of Stanford University Medical Center, discusses findings from a large population-based study suggesting lasting effects of lymphoma and its treatments: an increased incidence of autoimmune and infectious diseases (Abstract 198).
Joseph M. Connors, MD, of the British Columbia Cancer Agency, discusses study findings on a new front-line option: brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with previously untreated stage III or IV Hodgkin lymphoma (Abstract 6).
Gilles A. Salles, MD, PhD, of the Université de Lyon, discusses study findings on rituximab maintenance after induction immunochemotherapy and the significant long-term progression-free survival benefit over observation (Abstract 486).
Carla Casulo, MD, of the James P. Wilmot Cancer Center, discusses findings on POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma, using data from more than 5,000 patients in 13 clinical trials (Abstract 412).
Andrew M. Evens, DO, of Tufts University, discusses findings on the effectiveness of DLBCL-based therapy for patients whose disease fell between diffuse large B-cell and classical Hodgkin lymphoma (Abstract 375).
Mark J. Roschewski, MD, of the National Cancer Institute, discusses phase II study findings that showed DA-EPOCH-R cures most adult patients with Burkitt lymphoma, irrespective of HIV status (Abstract 188).
